Stockscreener 앱 받기
1.86
3.12%
-0.06
시간 외 거래:
1.86
전일 마감가:
$1.92
열려 있는:
$1.92
하루 거래량:
242.23K
Relative Volume:
0.37
시가총액:
$69.31M
수익:
$832.00K
순이익/손실:
$-135.12M
주가수익비율:
-0.3054
EPS:
-6.09
순현금흐름:
$-124.69M
1주 성능:
-1.59%
1개월 성능:
+19.23%
6개월 성능:
-66.90%
1년 성능:
-84.63%
1일 변동 폭
$1.85
$1.94
1주일 범위
$1.82
$1.95
52주 변동 폭
$1.42
$13.44
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
INO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.86 | 69.31M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 - Kilgore News Herald
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO to Present at Upcoming Scientific and Investor Conferences - The Bradford Era
INOVIO to Present at Upcoming Scientific and Investor Conferences | INO Stock News - GuruFocus
INOVIO Q1 2025 Earnings: DNA Medicine Leader to Reveal Latest Financial Performance May 13 - Stock Titan
INOVIO to Report First Quarter 2025 Financial Results on May 13, - GuruFocus
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Thursday, still underperforms market - MarketWatch
Human Papillomavirus Market Set for Breakthrough Expansion - openPR.com
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Bet on These 5 Top-Ranked Stocks With Rising P/E - Nasdaq
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial - ADVFN
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN
INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences - MyChesCo
Inovio (INO) Upgraded to Buy: Here's What You Should Know - MSN
INOVIO Reports Inducement Grant Under Inducement Plan - MarketScreener
Next-generation Covid-19 vaccines currently being tested - Yahoo Finance
INOVIO to Present at Upcoming Scientific Conferences | INO Stock News - GuruFocus
INOVIO to Present at Upcoming Scientific Conferences - Longview News-Journal
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
Inovio stock touches 52-week low at $1.47 amid market challenges - Investing.com Australia
Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire
HPV Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR | - openPR.com
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) - Yahoo Finance
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Sector Update: Health Care - MarketScreener
Inovio stock plunges to 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa
Inovio stock plunges to 52-week low at $1.74 amid market challenges - Investing.com Australia
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):